It has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership with MaxCyte, and Precision BioSciences filing for a $100 million IPO for its ‘off-the-sh
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
